1269755-53-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Trifluoromethyl-piperidine-3-carboxylic acid methyl ester is used as a building block for the synthesis of various pharmaceutical compounds due to its unique structural features, including the trifluoromethyl and piperidine groups.
Used in Pesticide Industry:
5-Trifluoromethyl-piperidine-3-carboxylic acid methyl ester is used as a key intermediate in the production of certain pesticides, leveraging its organofluorine and piperidine components to enhance the effectiveness of these agrochemicals.
Used in Research and Development:
5-Trifluoromethyl-piperidine-3-carboxylic acid methyl ester is used as a research compound for studying the effects of organofluorine and piperidine groups on the properties and reactivity of chemical entities, contributing to the advancement of organic chemistry and related fields.

Upstream product

• 436799-33-6 3-bromo-5-(trifluoromethyl)pyridine 
• 124236-38-0 methyl 5-(trifluoromethyl)nicotinate 
• 131747-40-5 5-(trifluoromethyl)pyridine-3-carboxylic acid 

Relevant academic research and scientific papers

LOX ENZYME INHIBITING METHODS AND COMPOSITIONS

This invention relates to compounds, pharmaceutical compositions and their use for treating fibrotic disorders, proliferative disorders, cardiovascular diseases, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, or neurological and neuropsychiatric conditions. One particular aspect of the inventions relates to inhibitors of the family of lysyl oxidase enzymes and their use as therapeutics for fibrotic disorders.

[1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor